[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Within the framework of clinical tests of Etolip (ethophylline clofibrate cps. 125 mg, Pharmaceutical Research Institute Modra) this preparation was administered to 28 patients with different types of hyperlipoproteinaemia in a specialized clinic for disorders of the lipid metabolism. The period of administration was four weeks, the dose 2 cps. twice a day. The effect of this new hypolipidaemic drug was compared with that of Lipathyl. Treatment with Etolip did not affect significantly the cholesterol and triacylglycerol levels, and the concentrations of apolipoprotein B and LDL-cholesterol did not change significantly. All these parameters were affected favourably and significantly by Lipanthyl. Etolip treatment had the favourable effect of elevating the HDL-cholesterol and apolipoprotein A-I level. Etolip was well tolerated by patients and no undesirable side-effects developed. The effects of Etolip as a hypolipidaemic agent are relatively small and are markedly lower than the effect of other registered hypolipidaemics available in the CSSR.
Ceska
R
R
III. interní katedra fakulty vseobecného lékarství UK, Praha.
Sobra
J
J
Procházková
R
R
Kvasilová
M
M
D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D011422:Propionates; C028764:etofylline clofibrate; D002994:Clofibrate; D011345:Fenofibrate
Etolip a Lipanthyl v lécbĕ hyperlipoproteinémií.